USPH · U S Physical Therapy Inc /Nv
$81.24
-1.52 (-1.84%)
At close · Aug 14
Market Cap
$1.21B
Shares
14.92M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$81.24
Open$81.80
Day$78.63–81.80
52W close$59.00–93.16
Avg vol 30d246K
Short int1.1M · 7.4% float · 4.2d
Short vol66%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+13%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
65%
mid-range
Momentum
relative strength
1-month return
+10%
trailing
6-month return
−3%
trailing
YTD return
+4%
this year
Relative strength
−17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $72 › 200d $76 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$48.8K over 90 days · 0% sells
Short interest
Rising
7.41% of float · ▲ +9.0% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
216 holders — near 3-yr low, contrarian setup
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
19%
expanding
EPS growth
−23%
Y/Y
Buyback
$25.0M
authorized
Balance sheet
$126.9M
net debt
Quant / Vol
risk profile
Volatility
39%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Adjusted EBITDA
· full year 2026
Non-GAAP
$102M – $106M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Adjusted EBITDA
· full-year 2025
$93M – $97M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
65%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $72 › 200d $76 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$48.8K over 90 days · 0% sells
Short interest
Rising
7.41% of float · ▲ +9.0% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
216 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $59
Now $81 · 65%
Range high $93
vs 200-day avg +7%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| IIP revenue | $31.7M | FY2026 Q2 | +9.1% |
|
|
|||
| Operating Results per share non-GAAP | $0.75 | Three Months Ended June 30, 2026 filing | — |
| Physical therapy net revenue | $182.36M | FY2026 Q2 | +8.4% |
|
|
|||
| Adjusted EBITDA (a non-GAAP measure) non-GAAP | $47.2M | Six Months Ended June 30, 2026 | — |
| Adjusted physical therapy operations gross profit margin non-GAAP | 18.1% | Six Months Ended June 30, 2026 | — |
| Adjusted salaries and related costs, as a percentage of revenue non-GAAP | 58.6% | Six Months Ended June 30, 2026 | — |
| Average daily visits per clinic | 33.5 | Q2 2026 | — |
|
|
|||
| Average Visits Per Clinic Per Day | 33.5 | Second quarter 2026 | — |
| Clinic count | 781 | as of June 30, 2026 | — |
| IIP gross profit margin | 20.4% | Six Months Ended June 30, 2026 | — |
| Mature revenue percent change | 3.1% | Six Months Ended June 30, 2026 | — |
| Number of clinics, end of period | 781 | Q2 2026 | — |
| Operating Results (a non-GAAP measure) non-GAAP | $18.23M | Six Months Ended June 30, 2026 | — |
| Operating Results per share (a non-GAAP measure) non-GAAP | $1.21 | Six Months Ended June 30, 2026 | — |
| Patient visits | 1,661,694 | Q2 2026 | — |
|
|
|||
| Physical therapy net revenue per patient visit | $107.59 | Q2 2026 | — |
| Physical therapy operations gross profit margin | 19.5% | Three Months Ended June 30, 2026 | — |
| Physical Therapy Revenue Per Patient Visit | $107.59 | Second quarter 2026 | — |
| Salaries and related costs, as a percentage of revenue | 58.9% | Six Months Ended June 30, 2026 | — |
| Year-to-date total additions | 19 | Six Months Ended June 30, 2026 | — |
| Year-to-date total closed or sold | -16 | Year-to-date 2026 | — |
| Corporate expense as a percentage of total revenue | 9.2% | Q1 2026 | — |
| IIP margin | 20.4% | Q1 2026 | — |
| Net rate per physical therapy visit | $106.49 | Q1 2026 | — |
| Physical therapy margin | 15.8% | Q1 2026 | — |
| Total clinic count | 783 | as of March 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
USPH
this stock
U S Physical Therapy Inc /Nv
|
$1.21B | +4.0% | +16.3% | — | 7.4% |
|
HCA
HCA Healthcare, Inc.
|
$89.77B | -13.3% | +7.1% | 13.9 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.87B | -4.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.57B | +34.8% | +0.9% | 10.3 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.65B | -0.2% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| USPH | +1.5% | +10.4% | -2.8% | +2.8% | +4.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.1% | +6.0% | -16.5% | -1.2% | -9.8% |
Capital returns
Latest dividend
$0.46
/ share · ex May 22, 2026
Declared · upcoming
$0.46
/ share · ex Aug 21, 2026
Paid (TTM)
$1.82
/ share · 4 payouts
Dividend yield (TTM, derived)
2.24%
Buyback program
· as of Aug 10, 2026
Authorized
$25.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.